V-Bio Ventures Portfolio Company Agomab Raises $100 Million Series C to Advance Fibrosis-focused Pipeline — Round led by Fidelity Management & Research Company with participation from new investors EQT Life Sciences, Canaan and Dawn […] October 11, 2023 · V-Bio Ventures
miDiagnostics announces collaboration with Galapagos to develop closed-flow, ultra-rapid CAR-T sterility test for its point-of-care CAR-T manufacturing platform Leuven, Belgium, November 10, 2023 – miDiagnostics NV, a global technology leader in point-of-care diagnostics, today announced a collaboration agreement […] November 10, 2023 · Quality by Design - Business & Communications
Pharmaceutical market access: how real-world data fuel better health beyond clinical trials Studies of a drug’s effectiveness and safety don’t end with clinical trials – they extend beyond market access when the […] September 27, 2023 · Janssen Pharmaceutica
V-Bio Ventures portfolio company Orionis Biosciences announces collaboration with Genentech to discover and develop molecular glue class medicines September 20, 2023, BOSTON, MA and GHENT, Belgium – Orionis Biosciences, a privately held life sciences company with an integrated […] September 20, 2023 · V-Bio Ventures
Augustine Therapeutics expands its leadership team and R&D platform, enters regulatory development. Leuven, Belgium, September 12th, 2023 – Augustine Therapeutics, a biotech company developing innovative therapies for neuromuscular and neurodegenerative disorders, announced […] September 12, 2023 · Quality by Design - Business & Communications
V-Bio Ventures portfolio company Corteria Pharmaceuticals raises EUR 65 million to advance its transformational medicines for cardiovascular diseases Ghent, Belgium, 7 September 2023 – Corteria Pharmaceuticals, a V-Bio Ventures portfolio company, is a biopharmaceutical company specialized in the […] September 7, 2023 · V-Bio Ventures
The obesity revolution: will new drugs bring about big changes? The recent approval of the obesity and diabetes drugs Wegovy, Ozempic, and Mounjaro has brought about big headlines, but are […] June 21, 2023 · V-Bio Ventures
V-Bio Ventures portfolio company Dualyx raises €40 million to progress Treg therapies for autoimmune diseases into the clinic Use of proceeds will enable the development of the Company’s lead autoimmune program DT-001, targeting TNFR2, as well as its […] May 15, 2023 · V-Bio Ventures
University Hospital Ghent and VIB are testing medication to treat COVID-19-associated respiratory illness University Hospital Ghent and VIB are assessing a drug called Leukine® to treat patients with respiratory illness associated with COVID-19. Major medical centers in [...] March 25, 2020 · BioVox
Belgian clinical trials for COVID-19 With COVID-19 cases soaring into the millions, and a vaccine still a ways off, patients are desperate for a treatment. […] May 5, 2020 · BioVox
Cell therapies: opportunities and challenges Recent activities in the cell therapy field have prompted many investment funds to pour fresh and increasing capital into this […] May 5, 2020 · V-Bio Ventures
Fundamental research leads to treatment breakthrough in rare genetic diseases A basic research breakthrough is improving patient lives, as researchers realized their rare genetic condition could be treated by repurposing […] June 8, 2020 · BioVox
The opioid epidemic: solutions to a painful problem Opioid misuse is a public health crisis that has resulted in debilitation, deaths, and significant social and economic impact. The […] July 7, 2020 · V-Bio Ventures
V-Bio invests into ExeVir Bio to accelerate development of new treatment conferring broad protection against Covid-19 Ghent, Belgium, 28 July 2020 – Today V-Bio Ventures announces its investment in a EUR 23 million Series A financing into ExeVir Bio. […] July 28, 2020 · V-Bio Ventures
Biodol Therapeutics receives EUR 4.5 million to progress its novel pain medication in a Series A led by V-Bio Ventures V-Bio Ventures, a leading Belgian life sciences VC, invests in Biodol Therapeutics, a French biotech specialized in next-generation chronic pain […] August 31, 2020 · V-Bio Ventures